PubMed · 14080889
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
L HOMER. 1963. METHDILAZINE INTOXICATION.. https://pubmed.ncbi.nlm.nih.gov/14080889/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
The capability of FT-Raman spectroscopy for the fast and non-destructive quantitative analysis of liquid formulations was tested and the results were compared to those obtained by HPLC. Diphenhydramine hydrochloride (DPH), the active ingredient of Benadryl, was determined in the presence of the numerous excipients of the elixir. A Raman calibration model was developed by measuring the peak intensities of different standard solutions of DPH vibration at 1003 cm(-1). Application of the calibration model on the peak intensity recorded from the as-received commercially available sample with 2.5 mg ml(-1) DPH nominal value yielded a value of 2.49+/-0.05 mg ml(-1) DPH. The reliability of this method was verified by testing it against the conventionally used HPLC. The results from both methods were in excellent agreement. The main advantage of Raman over HPLC method during routine analysis is that is considerably faster and less solvent consuming. Furthermore, Raman spectroscopy is non-destructive for the sample. On the other hand, the detection limit for Raman spectroscopy is much higher than the corresponding for the HPLC methodology.
Fexofenadine, a nonsedating antihistamine drug, is effective for the treatment of seasonal allergic rhinitis and chronic urticaria. Simultaneous administration of probenecid increases the plasma concentration of fexofenadine due to an inhibition of its renal elimination in healthy volunteers (Clin Pharmacol Ther 77:17-23, 2005). The purpose of the present study is to investigate the possibility that the drug-drug interaction between fexofenadine and probenecid involves the renal basolateral uptake process. The uptake of fexofenadine was determined in HEK293 cells expressing human organic anion transporter 1 (OAT1/SLC22A6), OAT2 (SLC22A7), OAT3 (SLC22A8), and organic cation transporter 2 (OCT2/SLC22A2). Only hOAT3-HEK showed a significantly greater accumulation of fexofenadine than that in vector-HEK, which was saturable with K(m) and V(max) values of 70.2 microM and 120 pmol/min/mg protein, respectively. Inhibition potency of probenecid for the uptake of fexofenadine was compared between hOAT3 and organic anion-transporting peptide 1B3 (hOATP1B3), a transporter responsible for the hepatic uptake of fexofenadine (Drug Metab Dispos 33:1477-1481, 2005). The K(i) values were determined to be 1.30 and 130 microM for hOAT3 and hOATP1B3, respectively, with Hill coefficients of 0.76 and 0.64, respectively. The K(i) value of probenecid for hOAT3, but not for hOATP1B3, was significantly lower than the maximum unbound plasma concentration of probenecid at clinical dosages. These results suggest that the renal drug-drug interaction between fexofenadine and probenecid is probably explained by an inhibition of the renal uptake of fexofenadine via hOAT3, at least in part.
Asthma is chronic inflammatory disease of the lower airway. In many cases, it is accompanied by allergic or non-allergic upper airway disease. While the treatment of the lower airway in bronchial asthma has been largely standardized based on diverse guidelines, for the simultaneous treatment of the upper airway, different strategies are in use. On the basis of collected study data, it has been shown that simultaneous pharmacotherapy of the upper airway comorbidities also has a positive effect on asthma. It has been shown that, when applied in good time, specific immunotherapy can prevent the development of asthma in some cases. This means that in patients with airway pathology, simultaneous treatment of the other level (upper or lower) should be considered.